MiniMed Group, Inc. 8-K

What Happened
MiniMed Group, Inc. announced that its Board increased from nine to eleven members and, effective June 29, 2026, appointed David Endicott and Linnea Burman as directors. Mr. Endicott will serve as a Class I director (term expires at the 2026 annual meeting) and join the Compensation and Talent Committee; the Board has determined he is independent. Ms. Burman will serve as a Class II director (term expires at the 2027 annual meeting) and, as a Medtronic employee while Medtronic remains an affiliate of MiniMed, will receive no director compensation until that affiliation ends.

Key Details

• Board size increased from 9 to 11; appointments effective June 29, 2026.
• David Endicott: current CEO of Alcon, former senior leader at Alcon Laboratories, Hospira and Allergan; Class I director with term expiring at MiniMed’s 2026 annual meeting; member of Compensation and Talent Committee; deemed independent.
• Linnea Burman: Senior VP & President, Neurovascular at Medtronic; Class II director with term expiring at the 2027 annual meeting; will not receive board pay while Medtronic is an affiliate.
• 2026 Annual Meeting set for Friday, October 9, 2026 at 9:00 a.m. PT (virtual); record date: close of business August 11, 2026.
• Filing deadlines: Rule 14a-8 stockholder proposals must be received by July 26, 2026; director nominations/other business per MiniMed bylaws must be received by July 17, 2026.

Why It Matters
New board members can influence corporate governance and strategic oversight. Endicott brings broad healthcare and executive experience and will participate on compensation oversight, while Burman brings deep medical-device industry experience and currently represents a strategic affiliate relationship with Medtronic. The announced meeting date, record date and proposal deadlines are important for investors who want to vote, submit proposals, or nominate directors at the 2026 annual meeting.